



VISTA PHARMACEUTICALS LTD

CIN: L24239TG1991PLC012264

Plot Nos.10 To 14 And 16 To 20, Apiic, Industrial Estate, Chityal, Gop Alaipalli Na,
Telangana -508254, India

e-mail: admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, 12th August, 2023.

To,
The General Manager,
Listing Department,
BSE Limited,
P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Sub: Financial Results for the quarter ended 30th June, 2023 – Regulation 33 (3) (a).

Ref: Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Saturday, 12th August, 2023 at 04:00 PM. at the corporate office of the Company, interalia, considered and approved the unaudited Financial Results for the quarter ended 30th June, 2023.

Copy of un-audited Financial Results for the quarter ended 30th June, 2023 and Limited review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
For Vista Pharmaceuticals Limited

DHANANJAYA ALLI
WHOLETEIME DIRECTOR
DIN: 00610909



Independent Auditor's Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited (“the Company”) for the quarter ended June 30,2023 and year to date results for the period April 01,2023 to June 30, 2023 (“the Statement ”) attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Regulation”)
2. This Statement, which is the responsibility of the company’s Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 “Interim Financial Reporting”, prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, “Review of Interim Financial Information Performed by the independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to


obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

FRNo: 009068S


D Ramakrishna Reddy



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 23209211BGYWLJ7836

Place: Hyderabad

Date: August 12, 2023

VISTA PHARMACEUTICALS LIMITED

CIN: L24239TG1991PLC012264

Statement of Un Audited financial results for the Quarter ended 30.06.2023

(Rs. in Lakhs)

S.No	Particulars	Quarter ended		Year Ended	
		June 30,2023	March 31,2023	June 30,2022	March 31,2023
		Un Audited	Audited	Un Audited	Audited
1	Income				
	a. Revenue from operations	198.10	100.37	0.00	100.37
	b. Other income	13.21	39.94	0.00	39.94
2	Total Income (a+b)	211.31	140.31	0.00	140.31
3	Expenses				
	a) Cost of Material Consumed	206.37	282.84	0.00	282.84
	b) Change in Inventories	(9.46)	-	-	-
	c) Employee benefits expense	41.73	24.97	5.10	50.87
	d) Finance costs	32.67	32.21	23.78	121.35
	e) Depreciation and amortization expense	17.34	15.56	15.40	61.76
	f) Other expenses	51.56	152.39	15.05	211.12
	Total Expenses	340.21	507.97	59.33	727.94
4	Profit before tax (2-3)	(128.91)	(367.66)	(59.33)	(587.63)
5	Tax expense				
	(1) Current tax	-	0.00	0.00	0.00
	(2) Deferred tax	(33.45)	108.87	(0.30)	83.83
	(3) Previous year Income tax adjustment	-	(105.26)	-	(105.26)
6	Net Profit for the Period (4-5)	(95.46)	(371.27)	(59.03)	(566.20)

7	Other comprehensive income (OCI)				
	Items that will not be reclassified Subsequently to profit or loss	0.12	2.07	(8.56)	(0.25)
	Tax on items that may not be reclassified to profit or loss	-	-	-	-
	Items that will be reclassified to profit or loss:	-			
	Total Other Comprehensive income	0.12	2.07	(8.56)	(0.25)
8	Total Comprehensive income (6+7)	-95.34	-369.20	-67.59	-566.45
9	Paid- up equity share capital(Face Value of Rs.2/- each)	855.34	751.30	735.88	751.30
10	Other Equity				
11	Earnings per equity share				
	(Face value of Rs.10/- each)				
	(1) Basic	-0.23	-1.00	-0.18	-1.54
	(2) Diluted	-0.15	-0.59	-0.18	-0.90

Notes:

- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- 2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 12th August , 2023
- 3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
4. Total Revenue for the current quarter is Rs.211.31 Lakhs compared to Rs.0.00 Lakhs for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs. 128.91 Lakhs compared to Profit Before tax of Rs. 59.33 Lakhs for the corresponding quarter of the previous year.
- 6.The Profit/(Loss) After tax for the current quarter is Rs.(95.46) Lakhs compared to Rs. (59.03) Lakhs for the corresponding quarter of the previous year.
- 7.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 8.The results for the quarter ended 30th June 2023 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.

Place:Hyderabad

Date:12.08.2023

For Vista Pharmaceuticals Limited

Y Divakar Reddy

Director

(DIN: 08574891)